Results 211 to 220 of about 110,363 (266)

Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10). [PDF]

BMJ Open
Ozaki Y, Koyama S, Morita S, Miyashita M, Tokuda E, Shimoi T, Fukuoka M, Masuda H, Takano Y, Shibata N, Yoshinami T, Murakami A, Tamaki K, Ishiguro H, Saji S, Miwa A, Matsunaga J, Zheng Y, Nishikawa H, Masuda N.   +19 more
europepmc   +1 more source

PRMT5/Sohlh2/Sirt1 Signaling Pathway in Vascular Endothelial Cells Modulates Lung Metastasis of Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
The cover image shows that vascular endothelial cells play an important role in lung metastasis of TNBC. Endothelial Sohlh2 acts as a gatekeeper against TNBC lung metastasis by limiting endothelial activation and tumor cell passage. PRMT5 reduces Sohlh2 stability, weakening this protective barrier.
Ruihong Zhang, Fengqin Wang, Lanlan Liu, Qi Zhang, Xiaoning Huo, Yanhui Nan, Yanli Dong, Yunling Xiao, Jing Hao   +8 more
wiley   +1 more source

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Systematic Review of Breast and Node Pathologic Response. [PDF]

J Surg Oncol
Cristófalo MM, Maesaka JY, Pereira DA, Nóbrega GB, Reis YN, Júnior JMS, Baracat EC, Filassi JR.   +7 more
europepmc   +1 more source

Enhanced Intracellular Stability and Translation Efficiency of mRNA Drugs by a 2‐arm mRNA Platform

Advanced Science, EarlyView.
We constructed a 2‐arm mRNA, characterized by a unique topology formed through the dimerization of two mRNA 3’ tails. The 2‐arm mRNA improves 3’ tail stability and resistance to nuclease degradation, resulting in an intracellular half‐life of up to 65 h. This method substantially enhances the translation capacity of mRNA drugs.
Xucong Teng, Jiahao Lin, Qiushuang Zhang, Xiangdong Zhang, Yicong Dai, Jinghong Li   +5 more
wiley   +1 more source

Collision tumor: a parathyroid adenoma unveiling subclinical widespread breast carcinoma: a case report. [PDF]

J Med Case Rep
Yacoub S, Bil Hadj Miled H, Mokni W, Elfkih H, Belakhder M, Mokni M.   +5 more
europepmc   +1 more source

Publication proportions for registered breast cancer trials: before and following the introduction of the ClinicalTrials.gov results database [PDF]

core   +1 more source

Selenium‐Based Nanoplatforms: An Emerging Theranostic Paradigm for Gynecological Cancers

Advanced Science, EarlyView.
This reivew summarizes Selenium as a multifunctional anticancer regulator in gynecological cancers. It reduces tumor risk, enhances therapeutic efficacy, and reduces treatment toxicity. Selenium also overcomes chemoraditherapy resistance, improving overall treatment outcomes. ABSTRACT Gynecological cancers present significant therapeutic challenges due
Hejing Liu, Yujia Zhou, Zihan Zhang, Rong Ma, Luyi Ruan, Liqing Miao, Boxin Zhang, Huihui Ji, Tianfeng Chen, Xueqiong Zhu   +9 more
wiley   +1 more source

A Rare Case of Adenoid Cystic Carcinoma in the Male Breast: Clinical Presentation and Histopathological Evaluation. [PDF]

Clin Case Rep
Tayebi N, Jahanbin B, Nozheh A.
europepmc   +1 more source

Decoding the Mechanism of Action of a Parasite TGFβ Antagonist Inspires the Creation of Cell‐Type‐Specific TGFβ Modulators

Advanced Science, EarlyView.
The mammalian TGFβ interacts with ubiquitously expressed TGFBR1 and TGFBR2, and current TGFβ‐targeting agents are non‐cell‐selective. The cooperative interaction of the modular parasite TGFβ antagonist with multiple host (co‐)receptors empowers the design of TGM chimeras and bispecific antibodies that activate or inhibit TGFβ signaling in a cell ...
Maarten van Dinther, Tristin Schwartze, Jiying Zhang, Kun Fan, Gerard van der Zon, Luke Power, Cynthia S. Hinck, Claire Ciancia, Ananya Mukundan, Roman Gonzalez‐Prieto, Peter van Veelen, Rick M. Maizels, Andrew P. Hinck, Peter ten Dijke   +13 more
wiley   +1 more source

Germline <i>BRCA</i> testing in routine clinical practice: a single-center experience. [PDF]

Pathol Oncol Res
Nikolényi A, Dobi Á, Sántha D, Kószó R, Iványi M, Horváth E, Enyedi MZ, Priskin K, Csányi B, Patócs A, Butz H, Papp J, Varga Z, Tóth R, Oláh J, Kahán Z.   +15 more
europepmc   +1 more source